Methods: Fifteen patients with confirmed HER2-positive breast cancer underwent simultaneous PET/MRI 5–7 d after receiving 77 ± 1.9 MBq of [89Zr]Zr-trastuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.